Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ProQR Therapeutics N.V.
ProQR Announces Second Quarter 2024 Operating and Financial Results
August 08, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 18, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces First Quarter 2024 Operating and Financial Results
May 09, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
May 08, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 23, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
April 22, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Year End 2023 Operating and Financial Results
March 13, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
February 15, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
January 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
January 05, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Second Quarter 2023 Operating and Financial Results
August 03, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
August 01, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
May 09, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Upcoming Investor Conferences in April and May
April 20, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
April 18, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
March 29, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
March 14, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR to Present at Upcoming Scientific and Industry Conferences
March 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
February 28, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
December 22, 2022
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
Lilly and ProQR to Expand RNA Editing Collaboration
December 22, 2022
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Tickers
PRQR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.